Compare ADMA Biologics Inc (ADMA) vs United Microelectronics Corp (UMC) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs United Microelectronics Corp — how do they compare? ADMA Biologics Inc trades at $9.24 (market cap $2.13B), while United Microelectronics Corp trades at $24.19 (market cap $60.80B). The key difference: United Microelectronics Corp is far larger — about 28.5× ADMA Biologics Inc's market cap, and United Microelectronics Corp pays a 1.73% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | UMC | |
|---|---|---|
Market Cap | $2.13B | $60.80B |
Sector | Health | Technology |
52-Week High | $20.38 | $28.02 |
52-Week Low | $7.60 | $6.58 |
Enterprise Value | $2.20B | $58.38B |
Dividend Yield | — | 1.73% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
UMC trades at $23.83, down 2.89% on the day, with a bullish technical signal from moving averages and recent earnings beats. Revenue grew to $237.55 billion in 2025, though net income margin compressed to 16.99%. The company maintains strong cash flow from operations and announced a $0.41 dividend for H2-26, reflecting financial stability amid competitive semiconductor market dynamics.
Outlook remains supported by specialty chip demand and 14nm eHV platform innovation, but valuation multiples like P/E of 41.94 suggest premium pricing. Risks include margin pressure and industry cyclicality, while analyst consensus leans hold with 53.33% neutral ratings, indicating cautious optimism for long-term growth.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About United Microelectronics Corp
Founded in 1980, United Microelectronics is the world's third-largest dedicated chip foundry, with 7% market share in 2021, according to Gartner, after TSMC and GlobalFoundries. UMC's headquarters are in Hsinchu, Taiwan, and it operates 12 fabs in Taiwan, Mainland China, Japan and Singapore, with additional sales offices in Europe, the U.S. and South Korea. UMC features a diverse customer base including Texas Instruments, MediaTek, Qualcomm, Broadcom, Xilinx and Realtek, supplying a wide range of products applied in communications, display, memory, automotive and more. UMC employs about 20,000 people.
Read more on UMC →
